American Migraine Foundation Highlights HeadaTerm2 in Its Latest Device Recommendations, Backed by Clinical Evidence

VANCOUVER, BC, June 16, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. is pleased to announce that its migraine relief device, HeadaTerm 2, is now featured on the American Migraine Foundation's (AMF) updated Device Corner, a patient education resource highlighting FDA-cleared neuromodulation devices for migraine treatment.

HeadaTerm 2 is a non-invasive, drug-free device designed to help manage migraine symptoms through external trigeminal nerve stimulation (eTNS). It delivers mild electrical impulses to the trigeminal nerve region to help regulate pain pathways associated with migraine onset. Its portable, user-friendly design makes it a practical solution for individuals seeking alternatives to pharmaceutical treatments.

HeadaTerm 2's inclusion on the AMF's Device Corner aligns with an increasing body of clinical evidence supporting its use. A randomized controlled trial published in The American Journal of Emergency Medicine (Hokenek et al., 2021) demonstrated a 69.66% reduction in migraine pain among participants using the device, with a lower reliance on rescue medications within two hours of treatment. These findings underscore the potential role of neuromodulation in both acute care settings and at-home use.

FDA-cleared and eligible for FSA/HSA reimbursement, HeadaTerm 2 offers a compelling option for those seeking effective migraine relief without medication-related side effects. As migraine continues to affect over one billion people worldwide, WAT Medical remains committed to developing evidence-based, accessible therapies for neurological conditions.

WAT Medical continues to invest in the research and development of wearable medical technologies that prioritize patient safety, portability, and clinical validation. The company's inclusion in the AMF Device Corner reflects its ongoing mission to expand access to drug-free treatment solutions for migraine and other chronic conditions.

References

1.      American Migraine Foundation. (2024). Device Corner: Neuromodulation Devices for Migraine. https://americanmigrainefoundation.org/device-corner/

2.      Hokenek, N. M., et al. (2021). Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomized controlled trial. The American Journal of Emergency Medicine, 39, 80–85.

3.      www.watmedical.com

4.      www.emeterm.com

References

1.      American Migraine Foundation. (2024). Device Corner: Neuromodulation Devices for Migraine. https://americanmigrainefoundation.org/device-corner/

2.      Hokenek, N. M., et al. (2021). Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomized controlled trial. The American Journal of Emergency Medicine, 39, 80–85.

3.      www.watmedical.com

4.      www.emeterm.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

American Migraine Foundation Highlights HeadaTerm2 in Its Latest Device Recommendations, Backed by Clinical Evidence

DIRIYAH, Saudi Arabia, Jan. 12, 2026 /PRNewswire/ -- Stemming from the joint announcement made on December 9, 2024, regarding the launch of two Trump-branded developments in Riyadh, Dar Al Arkan in collaboration with Dar Global and The Trump Organization are proud to reveal the first of those landmark projects, The Trump International Golf Club, Wadi Safar, a sprawling 2.6 million square meter site in Wadi Safar, the exclusive masterplan being developed by Diriyah Company.

 

 

The site will be home to the Trump International Golf Club, Wadi Safar, a world-class gated community featuring a Trump-branded championship golf course, a luxury Trump hotel, and premium residences overlooking the region's dramatic wadis and the golf vistas. Trump International Golf Club, Wadi Safar will blend world-class hospitality, architecture, and lifestyle in a setting that pays tribute to the cultural and natural heritage of the Kingdom.

Eric Trump, Executive Vice President of The Trump Organization, said: "We are proud to expand our presence with this landmark development in Wadi Safar. Trump International Golf Club, Wadi Safar will redefine luxury and excellence in the region, setting a new standard that reflects the brand's enduring commitment to quality, prestige and timeless elegance. We look forward to creating a destination that complements the rich heritage of the region while delivering a global standard of luxury living."

Yousef Al Shelash, Chairman of Dar Al Arkan, said: "This new project represents a vision to deliver a destination that captures the prestige and the legacy of the Trump brand. With Dar Global leading the development, we are confident this will become a flagship destination not just for Saudi Arabia, but for the world."

Ziad El Chaar, CEO of Dar Global, added: "Dar Global is proud to collaborate with Diriyah Company and Dar Al Arkan on the development of Trump International Golf Club, Wadi Safar. We have delivered landmark projects across Europe and the GCC in partnership with globally recognized luxury brands. Bringing this experience to the Diriyah project, we will deliver a destination that combines heritage, elegance, and world-class standards, making Trump International Golf Club, Wadi Safar a truly iconic address."

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

DAR AL ARKAN, IN COLLABORATION WITH DAR GLOBAL AND THE TRUMP ORGANIZATION, TO DEVELOP TRUMP INTERNATIONAL GOLF CLUB, WADI SAFAR - THE FIRST OF TWO LANDMARK PROJECTS IN RIYADH